Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2i in HFrEF
NCT06065280Completed
- Sponsor
- Damanhour University
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of empagliflozin and dapagliflozin in heart failure with reduced ejection fraction (HFrEF) (4 arms), sponsored by Damanhour University. Primary endpoints: Neopterin Concentration at 3 months, Complete Echocardiography monitoring for improvements at 3 months and 1 more. Started Nov 2022; status: completed.
02
Drugs
empagliflozindapagliflozin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT06065280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06065280.